Article
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Clinical colorectal cancer - 1 Dec 2011
Mitchell Edith P, Piperdi Bilal, Lacouture Mario E, Shearer Heather, Iannotti Nicholas, Pillai Madhavan V, Xu Feng, Yassine Mohamed
Abstract excerpt
BACKGROUND: Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is used as monotherapy for chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type (WT) KRAS tumors. Although skin toxicities are the most common adverse events associated with EGFR inhibitors, the differences in efficacy and safety between pre-emptive and reactive skin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.